- Home
- PMX vs KRRO Comparison
PMX vs KRRO Comparison
Compare PMX & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMX
- KRRO
- Stock Information
- Founded
- PMX 2002
- KRRO 2014
- Country
- PMX United States
- KRRO United States
- Employees
- PMX N/A
- KRRO N/A
- Industry
- PMX Trusts Except Educational Religious and Charitable
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- PMX Finance
- KRRO Health Care
- Exchange
- PMX Nasdaq
- KRRO Nasdaq
- Market Cap
- PMX 240.0M
- KRRO 209.6M
- IPO Year
- PMX N/A
- KRRO 2019
- Fundamental
- Price
- PMX $6.69
- KRRO $14.00
- Analyst Decision
- PMX
- KRRO Strong Buy
- Analyst Count
- PMX 0
- KRRO 7
- Target Price
- PMX N/A
- KRRO $106.33
- AVG Volume (30 Days)
- PMX 101.5K
- KRRO 107.3K
- Earning Date
- PMX 01-01-0001
- KRRO 05-13-2025
- Dividend Yield
- PMX 5.28%
- KRRO N/A
- EPS Growth
- PMX N/A
- KRRO N/A
- EPS
- PMX N/A
- KRRO N/A
- Revenue
- PMX N/A
- KRRO $2,271,000.00
- Revenue This Year
- PMX N/A
- KRRO N/A
- Revenue Next Year
- PMX N/A
- KRRO $20.00
- P/E Ratio
- PMX N/A
- KRRO N/A
- Revenue Growth
- PMX N/A
- KRRO N/A
- 52 Week Low
- PMX $6.09
- KRRO $11.13
- 52 Week High
- PMX $8.47
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- PMX 36.05
- KRRO 33.77
- Support Level
- PMX $6.60
- KRRO $13.07
- Resistance Level
- PMX $6.80
- KRRO $15.30
- Average True Range (ATR)
- PMX 0.16
- KRRO 1.87
- MACD
- PMX -0.01
- KRRO 0.29
- Stochastic Oscillator
- PMX 35.56
- KRRO 35.66
About PMX PIMCO Municipal Income Fund III of Beneficial Interest
PIMCO Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as transportation, healthcare, and others.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.